Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease by unknown
Shin et al. BMC Neuroscience  (2015) 16:23 
DOI 10.1186/s12868-015-0163-5RESEARCH ARTICLE Open AccessGypenosides attenuate the development
of L-DOPA-induced dyskinesia in
6-hydroxydopamine-lesioned rat
model of Parkinson’s disease
Keon Sung Shin, Ting Ting Zhao, Keun Hong Park, Hyun Jin Park, Bang Yeon Hwang, Chong Kil Lee
and Myung Koo Lee*Abstract
Background: Gypenosides (GPS) and ethanol extract of Gynostemma pentaphyllum (GP-EX) show anxiolytic effects
on affective disorders in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of Parkinson’s disease
(PD). Long-term administration of L-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of severe motor
side effects such as L-DOPA-induced-dyskinesia (LID) in PD. The present study investigated the effects of GPS and
GP-EX on LID in a 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD.
Results: Daily administration of L-DOPA (25 mg/kg) in the 6-OHDA-lesioned rat model of PD for 22 days induced
expression of LID, which was determined by the body and locomotive AIMs scores and contralateral rotational
behaviors. However, co-treatments of GPS (25 and 50 mg/kg) or GP-EX (50 mg/kg) with L-DOPA significantly attenuated
the development of LID without compromising the anti-parkinsonian effects of L-DOPA. In addition, the increases in
ΔFosB expression and ERK1/2 phosphorylation in 6-OHDA-lesioned rats induced by L-DOPA administration were
significantly reduced by co-treatment with GPS (25 and 50 mg/kg) or GP-EX (50 mg/kg).
Conclusion: These results suggest that GPS (25 and 50 mg/kg) and GP-EX (50 mg/kg) effectively attenuate the
development of LID by modulating the biomarker activities of ΔFosB expression and ERK1/2 phosphorylation in
the 6-OHDA-lesioned rat model of PD. GPS and GP-EX will be useful adjuvant therapeutics for LID in PD.
Keywords: Gynostemma pentaphyllum, 6-Hydroxydopamine-lesioned rats, Dyskinesia, Body and locomotive AIMs
scores, ΔFosB, ERK1/2, Adjuvant therapeuticsBackground
Parkinson’s disease (PD) is a progressive neurological
disorder mainly due to the degeneration of dopaminergic
neuronal cells in the substantia nigra pars compacta [1].
The precursor of dopamine, L-3,4-dihydroxyphenylala-
nine (L-DOPA), is the most effective known therapy for
controlling the motor symptoms in PD such as slowness,
rigidity, resting tremor, and postural instability [2,3].
However, chronic L-DOPA administration results in a
loss of drug efficacy and irreversible adverse effects, and* Correspondence: myklee@chungbuk.ac.kr
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tions such as L-DOPA-induced-dyskinesia (LID) [4].
Typically, dyskinesia can occur in association with high
concentrations of L-DOPA in the brain and maximum
improvement in the motor responses [5,6]. The most
common type of dyskinesia called peak-dose dyskinesia,
occurs throughout the “on” time period to response of
L-DOPA administration.
Although the mechanisms underlying the development
and expression of LID are complex, the development of
LID is associated with changes in the gene and protein
expressions of ΔFosB and extracellular signal-regulated
kinases (ERK1/2) in nigral dopamine cell loss [7,8]. LID
increases striatal levels of ΔFosB and ERK1/2 [7,8].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(6-OHDA)-lesioned rats also induces FosB-like protein
ΔFosB in the dopamine-denervated striatum that develops
dyskinesias [9]. ΔFosB protein is induced by L-DOPA
administration in the striatum of 6-OHDA-lesioned rats
[8]. In addition, increased ERK1/2 phosphorylation by
dopamine agonists in 6-OHDA-lesioned striatal neurons
is a possible mechanism of LID [10,11]. ERK1/2 phosphor-
ylation correlates with increased ΔFosB and dyskinesia in
the depleted striatum of 6-OHDA-lesioned rats [8]. There-
fore, ΔFosB expression and ERK1/2 phosphorylation in
the striatum are implicated in the development of LID as
biological molecular markers [8,9].
Gynostemma pentaphyllum Makino (Cucurbitaceae)
(GP) is a well-known herbal medicinal plant in Southeast
Asia. GP contains approximately 90 dammarane-type
glycosides (Gynostemma total saponins, gypenosides; GPS),
flavonoids, polysaccharides, amino acids, vitamins, and
some essential elements [12]. Recently, GPS has been
shown to have anxiolytic effects on affective disorders
and neuroprotective effects in 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine (MPTP)-lesioned mouse model of
PD [13,14]. In addition, ethanol extract from GP (GP-EX)
protects the dopaminergic neurons in 6-OHDA-lesioned
rat model of PD [15]. GP-EX also has anti-stress effects
in mice [16].
Although GPS has therapeutic benefits for several neu-
rodegenerative diseases including PD, the effects of GPS
on the development of LID have not been identified yet.
In this study, therefore, we examined the effects of GPS
and GP-EX on LID using the rat model of LID. After treat-
ments with GPS and GP-EX in L-DOPA-administered
6-OHDA-lesioned rats, LID was analyzed by using the
score of abnormal involuntary movements (AIMs) (body
AIMs score and locomotive AIM score), contralateralFigure 1 Experimental design. Rats (SD, male, 200–250 g) were divided int
L-DOPA-treated group, L-DOPA and GPS (25 or 50 mg/kg)-treated group, L
established by 6-OHDA lesion (8 μg/2 μl). Three weeks after the 6-OHDA le
the efficacy of the 6-OHDA lesion. L-DOPA (25 mg/kg, i.p.) and benserazide
once a day for 22 days. Either GPS (25 and 50 mg/kg, p.o.) or GP-EX (50 mg
22 days. The AIMs were scored for 1 min every 20 min for total 180 min af
measurements, the animals were sacrificed for biochemical analyses.rotational behaviors, and the biomarker activities of
ΔFosB expression and ERK1/2 phosphorylation.
Results
Effects of GPS and GP-EX on LID
In order to measure the effects of GPS and GP-EX on
LID, the treatment schedule including the behavioral
and biochemical analyses is presented in Figure 1. The
body AIMs score (total AIMs score; the integrated axial,
limb, and orolingual AIMs scores) and locomotive AIMs
score using the different dyskinesia subtypes (axial, limb,
orolingual, and locomotive AIMs score) were analyzed
separately. The daily repeated administration of L-DOPA
(25 mg/kg) induced an increase over time in the body
AIMs score in 6-OHDA-lesioned rats. LID by the body
AIMs score was observed at day-4 and continued to
increase at day-10, reaching its maximum at day-13 and
day-16 (Figure 2A). The body AIMs score of LID was
slightly decreased at day-19 and day-22, which was com-
parable with the previously reported results [17]. In this
study, the behavioral tests and biochemical analyses were
examined for 22 days.
The body AIMs score and locomotive AIMs score
were not affected in the sham-operated rats, which
had unaffected AIMs scores. However, treatment with
GPS (25 and 50 mg/kg) or GP-EX (50 mg/kg) in 6-
OHDA-lesioned rats treated with L-DOPA for 22
days displayed much less severe dyskinesia (P < 0.05),
compared with 6-OHDA-lesioned rats treated with L-
DOPA (Figure 2A and B).
Next, the effects of GPS and GP-EX on the different
dyskinesia subtypes such as the body AIMs score (the
axial, limb and orolingual AIMs score) and locomotive
AIMs score were analyzed. The axial, limb and orolin-
gual AIMs score was increased by the daily repeatedo five groups [8–10 animals per each group: saline-treated group,
-DOPA and GP-EX (50 mg/kg)-treated group] and PD models were
sion, the apomorphine-induced rotational test was carried out to assess
(15 mg/kg, i.p.) treatment was started 6 weeks after the 6-OHDA lesion
/kg, p.o.) was given 30 min prior to L-DOPA treatment once a day for
ter L-DOPA treatment on the indicated day. On day-22, after behavioral
Figure 2 Effects of GPS and GP-EX on body AIMs score in 6-OHDA-lesioned rats. L-DOPA (25 mg/kg, i.p.) and benserazide (15 mg/kg, i.p.) treatment
was started 6 weeks after the 6-OHDA lesion once a day for 22 days. Either GPS (25 and 50 mg/kg, p.o.) or GP-EX (50 mg/kg, p.o.) was given 30 min
prior to L-DOPA treatment once a day for 22 days. The axial, limb, and orolingual AIMs were calculated by adding each of the individual dyskinesia
scores as body AIMs. A: body AIMs; B: area under the curve of body AIMs. The results are expressed as mean ± S.E.M. for 8–10 animals/group.
–■–, saline treatment; −□–, L-DOPA; −▲–, L-DOPA + GP-EX (50 mg/kg); −◆–, L-DOPA + GPS (25 mg/kg); −○–, L-DOPA + GPS (50 mg/kg).
A: *P < 0.05 compared with saline-treated group at each treatment day; #P < 0.05 compared with L-DOPA alone-treated group at each treatment
day (non-parametric Kruskal-Wallis one-way ANOVA test); †P < 0.05 compared with the score of day-1 (Friedman repeated measures ANOVA test),
B: §P < 0.05 compared with saline-treated group; §§P < 0.05 compared with L-DOPA alone-treated group (non-parametric Kruskal-Wallis one-way
ANOVA test).
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6-OHDA-lesioned rats (Figure 3A–D). In contrast, daily
repeated treatments with GPS (25 and 50 mg/kg) or
GP-EX (50 mg/kg) prior to L-DOPA administration in
6-OHDA-lesioned rats treated with L-DOPA signifi-
cantly attenuated the development of L-DOPA-induced
body AIMs (Figure 3A–C).
In addition, the locomotive AIMs score was not af-
fected by repeated treatments with L-DOPA (25 mg/kg)
in 6-OHDA-lesioned rats. Treatment with GPS (25 and
50 mg/kg) or GP-EX (50 mg/kg) in 6-OHDA-lesioned
rats treated with L-DOPA also did not reduce the
locomotive AIMs score, compared with GPS- or GP-
EX-untreated group (Figure 3D).Effects of GPS and GP-EX on contralateral rotational
behavior
GPS (25 and 50 mg/kg) and GP-EX (50 mg/kg) were
co-treated with L-DOPA administration of 6-OHDA-
lesioned rats to determine their effects on rotational
behavior. L-DOPA administration (25 mg/kg) in 6-
OHDA-lesioned rats produced a significant increase in
contralateral turns, compared with saline-treated 6-
OHDA-lesioned group (Figure 4). Treatment with GPS
(25 and 50 mg/kg) or GP-EX (50 mg/kg) for 22 days
in 6-OHDA-lesioned rats treated with L-DOPA also
slightly increased the number of contralateral turns,
compared with 6-OHDA-lesioned rats treated with L-
DOPA, but it was not significant (Figure 4). In addition,
a slight enhancement of contralateral rotations on the
anti-parkinsonian effects of L-DOPA was observed inGPS (50 mg/kg)-treated group (Figure 4). However, no
significant interaction between L-DOPA and GPS or
GP-EX was observed (Figure 4).Effects of GPS and GP-EX on ΔFosB expression
Degeneration of dopaminergic neurons by both 6-OHDA
and L-DOPA treatment induced an overall increase in
striatal levels of ΔFosB, which was measured by western
blot (Figure 5). L-DOPA (25 mg/kg) administration
resulted in a 2.5-fold (P < 0.05) increase in expression
of ΔFosB in 6-OHDA-lesioned rats, compared with
6-OHDA-lesioned rats treated with saline (Figure 5).
However, co-treatment with GPS (25 and 50 mg/kg)
prior to L-DOPA administration decreased the expres-
sion of ΔFosB to 1.9- and 1.5-fold (P < 0.05), compared
with 6-OHDA-lesioned rats treated with L-DOPA
(Figure 5). Co-treatment with GP-EX (50 mg/kg) prior
to L-DOPA administration also decreased the expression
of ΔFosB (2.0-fold, P < 0.05), compared with 6-OHDA-
lesioned rats treated with L-DOPA (Figure 5).Effects of GPS and GP-EX on ERK1/2 phosphorylation
L-DOPA (25 mg/kg) administration resulted in 3.2-fold
(P < 0.05) increase in ERK1/2 phosphorylation in 6-OHDA-
lesioned rats, compared with 6-OHDA-lesioned rats treated
with saline (Figure 6). Co-treatment with GPS (25 and
50 mg/kg) prior to L-DOPA administration (25 mg/kg)
reduced ERK1/2 phosphorylation (2.4-fold and 1.7-fold,
P < 0.05) respectively, compared with 6-OHDA-lesioned
rats treated with L-DOPA (Figure 6). Co-treatment with
GP-EX (50 mg/kg) prior to L-DOPA administration
Figure 3 Effects of GPS and GP-EX on L-DOPA-induced AIMs in 6-OHDA-lesioned rats. L-DOPA (25 mg/kg, i.p.) and benserazide (15 mg/kg, i.p.)
treatment was started 6 weeks after the 6-OHDA lesion once a day for 22 days. Either GPS (25 and 50 mg/kg, p.o.) or GP-EX (50 mg/kg, p.o.) was
given 30 min prior to L-DOPA treatment once a day for 22 days. The AIMs were scored for 1 min every 20 min for total 180 min after L-DOPA
treatment on the indicated day according to the description in the Materials and methods section. A: axial AIMS; B: limb AIMs; C: orolingual AIMs;
D: locomotive AIMs. The results are expressed as mean ± S.E.M. for 8–10 animals/group. –■–, saline treatment; −□–, L-DOPA; −▲–, L-DOPA+ GP-EX
(50 mg/kg); −◆–, L-DOPA+ GPS (25 mg/kg); −○–, L-DOPA+ GPS (50 mg/kg). *P < 0.05 compared with saline-treated group at each treatment day;
#P < 0.05 compared with L-DOPA alone-treated group at each treatment day (non-parametric Kruskal-Wallis one-way ANOVA test); †P < 0.05
compared with the score of day-1 (Friedman repeated measures ANOVA test).
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(2.3-fold, P < 0.05), compared with 6-OHDA-lesioned
rats treated with L-DOPA (Figure 6).
Discussion
GPS and GP-EX showed anxiolytic effects on affective
disorders in MPTP-lesioned mouse model of PD with
or without L-DOPA administration [13]. GPS (100–
200 mg/kg) showed protective effects in MPTP-lesioned
mouse model of PD [14]. GP-EX also has protective
effects on neurotoxicity by modulating TH neuronal celldeath and dopamine levels in 6-OHDA-lesioned rat
model of PD [15]. On the basis of these results, we in-
vestigated the effects of GPS and GP-EX on the devel-
opments of LID in 6-OHDA-lesioned rat model of PD.
The body AIMs score such as axial, limb and orolingual
AIMs score is increased in LID in 6-OHDA-lesioned
animal model of PD [17]. However, the locomotive
AIMs score does not necessarily provide a behavioral
correlate of LID [18]. In this study, LID expression was
significantly increased by chronic L-DOPA administra-
tion for 22 days in 6-OHDA-lesioned rats (Figure 2).
Figure 4 Effects of GPS and GP-EX on contralateral rotation behavior in 6-OHDA-lesioned rats. L-DOPA (25 mg/kg, i.p.) and benserazide (15 mg/
kg, i.p.) treatment was started 6 weeks after the 6-OHDA-lesion once a day for 22 days. GPS (25 and 50 mg/kg, p.o.) and GP-EX (50 mg/kg, p.o.)
were given 30 min prior to L-DOPA treatment once a day for 22 days. The contralateral rotation behavior was monitored for 1 h on the indicated day.
The results are expressed as mean ± S.E.M. for 8–10 animals/group. –■–, saline treatment; −□–, L-DOPA; −▲–, L-DOPA + GP-EX (50 mg/kg);
−◆–, L-DOPA + GPS (25 mg/kg); −○–, L-DOPA+ GPS (50 mg/kg). *P < 0.05 compared with saline-treated group at each treatment day (non-parametric
Kruskal-Wallis one-way ANOVA test); †P < 0.05 compared with the score of day-1 (Friedman repeated measures ANOVA test).
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GP-EX (50 mg/kg) prior to L-DOPA administration
significantly attenuated the development of LID as
determined by body AIMs score (Figures 2 and 3A–C).
In contrast, the locomotive AIMs score was not altered
by co-treatment with GPS (25 and 50 mg/kg) or GP-EX
(50 mg/kg) prior to L-DOPA administration (Figure 3).
L-DOPA treatment increased the number of contra-
lateral rotations in 6-OHDA-lesioned rats, indicating
behavior sensitization. The contralateral rotations are
indicative of anti-parkinsonian efficacy. However, it is also
suggested that the rotational behaviors are a dyskinesia
symptom [17]. In this study, treatment with GPS (25 and
50 mg/kg) or GP-EX (50 mg/kg) in 6-OHDA-lesioned
rats administered with L-DOPA slightly increased the
contralateral rotations, but it was not significant (Figure 4),
suggesting that GPS (25 and 50 mg/kg) and GP-EX
(50 mg/kg) treatment did not produce a significant be-
havior sensitization. Furthermore, these results indicate
that the anti-dyskinetic efficacy of GPS and GP-EX is
not due to an attenuation of L-DOPA efficacy.
The striatal ΔFosB is induced in the development of
LID in PD rat models [9]. 6-OHDA-lesioned rats and
L-DOPA administration in saline-lesioned rats do not
affect ΔFosB [19,20]. In addition, the phosphorylated
levels of ERK1/2 are not affected by saline treatment in6-OHDA-lesioned rats [21]. The pronounced phosphor-
ylation of ERK1/2 in the striatum of 6-OHDA-lesioned
rats provides a molecular counterpart to the induction
of AIMs by L-DOPA administration [21]. The present
study showed the significant ΔFosB expression and
ERK1/2 phosphorylation after L-DOPA administration
in the striatum of 6-OHDA-lesioned rats (Figures 5
and 6). However, the increased ΔFosB expression after
L-DOPA administration in the striatum of 6-OHDA-
lesioned rats was reduced by treatment with either GPS
(25 and 50 mg/kg) or GP-EX (50 mg/kg) prior to L-DOPA
administration (Figure 5). GPS (25 and 50 mg/kg) and
GP-EX (50 mg/kg) also decreased ERK1/2 phosphoryl-
ation in 6-OHDA-lesioned rats after L-DOPA adminis-
tration. These results suggest that the effects of GPS
and GP-EX on the development of LID are mediated by
the modulation of ΔFosB expression and ERK1/2 phos-
phorylation in 6-OHDA-lesioned rats.
It is reported that LID affects up to 80% of PD patients
after L-DOPA administration for 5–10 years and some
of PD patients have to stop the therapy due to severe
LID [22], which is difficult to treat. The pathogenesis of
LID remains incompletely understood presently. How-
ever, it is known that dyskinesias appear only after dopa-
minergic therapy and the presence of dopaminergic cell
loss in the substantia nigra [23].
Figure 5 Effects of GPS and GP-EX on L-DOPA-induced expression of ΔFosB in 6-OHDA-lesioned rats. ΔFosB expression was evaluated by western
blotting of proteins extracted from the 6-OHDA-lesioned striatum 1 h after the final L-DOPA treatment. Immunoblot images were detected by
antibodies against ΔFosB and β-actin using western blotting analysis. Values of the relative density ratios of ΔFosB expression, which are normalized by
β-actin, are expressed in arbitrary units as compared with saline-treated group or L-DOPA alone-treated group. The position of molecular size markers
is indicated as kDa. The results are expressed as mean ± S.E.M. for 8–10 animals/group. *P < 0.05 compared with saline-treated group; #P < 0.05
compared with L-DOPA alone-treated group (one-way ANOVA followed by Tukey’s test).
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dopamine-depleted striatum results from pulsatile stimu-
lation of postsynaptic dopamine receptor [24]. The
increases in ΔFosB expression after L-DOPA adminis-
tration have been shown to be associated with the
supersensitive responses to L-DOPA induced by dopa-
minergic stimulation in dopamine depleted striatum [8].
The sustained activation of ERK1/2 by L-DOPA admin-
istration also reflects the supersensitivity of dopamine
receptor-dependent signaling in dopamine-depleted stri-
atum [21]. In addition, L-DOPA induces ΔFosB expression
in striatal neurons by involving D1 receptors and ERK1/2
phosphorylation [8,10]. In 6-OHDA-lesioned striatum,
both D1 and D2 receptor agonists have been reported to
significantly induce ERK1/2 activation [10,11]. These
results suggest that changes in ΔFosB expression and
ERK signaling system are associated with the super-
sensitive responses to dopaminergic stimulation, which
is implicated in LID in dopamine-depleted striatum.
Recently, the sustained ERK1/2 phosphorylation in-
duced by L-DOPA has been shown to possibly lead to
dopaminergic neuronal cell death in PC12 cells [25],
and GPS has shown protective effects on 1-methyl-4-
phenylpyridinium (MPP+)-induced oxidative injury of
dopaminergic neurons in primary culture [26]. Therefore,the protective effects of GPS and GP-EX on dopaminergic
neuronal cells can be involved in the inhibition of the
development of LID.
GPS is a potent free radical scavenger, which strongly
increases the superoxide dismutase activity [27]. GPS
shows protective effects in aortic endothelial cells against
oxidative damage [28] and on oxidative stress induced by
glutamate-induced neurotoxicity [29]. GP-EX also has
been reported to have anti-stress and immunomodulatory
effects in mice [16,30]. GP-EX has a protective function
against chronic stress by modulation of c-Fos expression
[16]. Furthermore, L-DOPA increases nitric oxide produc-
tion in the striatum which is associated with PD [31].
Neuronal nitric oxide synthase inhibition attenuates the
expression of LID [32]. Daily repeated L-DOPA adminis-
tration also increases the nitric oxide generation through
activation of neural nitric oxide synthase and this nitric
oxide develops LID through a post-synaptic mechanism
by the accumulation of ΔFosB [33]. In contrast, it is sug-
gested that the development of LID is closely associated
with progression of pre-synaptic dopaminergic neurode-
generation in the substantia nigra [34]. It is therefore
suggested that the ameliorating effects of GPS and
GP-EX on LID might be mediated by scavenging the
ROS formation in the striatum of 6-OHDA-lesioned
Figure 6 Effects of GPS and GP-EX on L-DOPA-induced phosphorylation of ERK1/2 in 6-OHDA-lesioned rats. ERK1/2 phosphorylation (p-ERK1/2)
was evaluated by western blotting of proteins extracted from the 6-OHDA-lesioned striatum 1 h after the final L-DOPA treatment. Immunoblot
images were detected by antibodies against phospho-ERK1/2, ERK1/2 and β-actin using western blotting analysis. Values of the relative density
ratios of p-ERK1/2/ERK1/2 are normalized and expressed in arbitrary units as compared with saline-treated group or L-DOPA alone-treated group.
The position of molecular size markers is indicated as kDa. The results are expressed as mean ± S.E.M. for 8–10 animals/group. *P < 0.05 compared
with saline-treated group; #P < 0.05 compared with L-DOPA alone-treated group (one-way ANOVA followed by Tukey’s test).
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on reducing ΔFosB levels are involved in the post-synaptic
mechanism needs to be studied further.
The dose of GPS (50–200 mg/kg) and GP-EX (50–
400 mg/kg) treatments does not exhibit adverse effects,
such as weight loss, diarrhea, vomiting, and death [16].
The LD50 values of total GPS are 755–838 mg/kg (injected
into the abdominal cavity) and 402 (±18.2 mg/kg, i.p.)
in mice [35], indicating that GPS and GP-EX are low
toxicity therapeutic agents.
Conclusion
The present study demonstrated that GPS (25 and
50 mg/kg) and GP-EX (50 mg/kg) not only attenuated the
development of LID, but also reduced both ΔFosB
expression and ERK1/2 phosphorylation in 6-OHDA-
lesioned rats treated with chronic L-DOPA. GPS and
GP-EX also had no negative effects on the anti-
parkinsonian efficacy of L-DOPA, which was defined by
the contralateral rotational tests. It is therefore pro-
posed that GPS and GP-EX as very low toxic agents can
be helpful in preventing the L-DOPA-induced adverse
or toxic effects for PD patients, as well as in slowing
down the progression of LID. The clinical applications
need to be studied further.Methods
Materials
GPS was purchased from Ankang Dongke Maidisen
Nature Pharmaceutical Co. (purity > 99%, confirmed by
HPLC analysis) (Xi’an, China) [14,29]. GP was obtained
from the Wonkwang Food Manufacturing Co. (Geochang,
Korea) and a voucher specimen of the herbal leaves of
GP was deposited at the herbarium of the College of
Pharmacy, Chungbuk National University (Cheongju,
Korea). The air-dried leaves of GP (1 kg) were extracted
with ethanol (80%, v/v) and the ethanol extracts were
evaporated to dryness under reduced pressure and
temperature (GP-EX, 97.2 g, yield, 9.7%, w/w).
L-DOPA, 6-OHDA, benserazide hydrochloride, and
apomorphine were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Rabbit polyclonal primary antibodies
and anti-rabbit IgG HRP-linked secondary antibodies
against ERK1/2, phospho-ERK1/2, ΔFosB and β-actin
were purchased from Cell Signaling Technology Inc.
(Beverly, MA, USA). All other chemicals were of analyt-
ical grade.
Experimental animals
Rats (Sprague–Dawley, male, 200–250 g) were purchased
from Samtako (Osan, Korea) and housed under standard
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and illumination (12-h light–dark cycle lighted on at
07:00) with ad libitum access to standard rat food and
water. All experimental procedures were approved by
the guidelines of Animal Ethics Committee of Chungbuk
National University Laboratory Animal Research Center
(Approval no. CBNUA-708-141-01) and were con-
ducted according to the National Institutes of Health
(NIH) guidelines.
Unilateral 6-OHDA lesion
Unilateral 6-OHDA lesions were conducted as described
previously [11,17]. The rats were anesthetized intraperito-
neally with Zoletil 50 (100 mg/kg, Virbac, Carros, France)
and placed in a stereotaxic stand (David Kopf Instruments,
Tujunga, CA, USA). The coordinates for the medial fore-
brain bundle were measured accurately (antero-posterior,
AP: −2.5 mm; medio-lateral, ML: +2.0 mm; dorso-ventral,
DV: −8.5 mm; relative to bregma). Next, 6-OHDA
(8 μg/2 μl in saline solution containing 0.05% of L-ascorbic
acid) was single injected into the left medial forebrain
bundle at 1 μl/min using a Hamilton syringe. After the
injection, the needle was left in place for 5 min before
being retracted in order to allow for complete diffusion
of the medium. The rats were left in the stand until they
had recovered from the anesthesia. In order to assess
the efficacy of the lesion, all rats were tested for apo-
morphine (0.5 mg/kg, s.c.)-induced rotation at 3 weeks
after the 6-OHDA lesions. Rats showing more than 150
rotations/30 min were selected for this study [36]. In
these states, the striatal levels of dopamine in 6-OHDA-
lesioned rats decreased to 40.9–47.1% as compared with
control group (dopamine levels of control group, 7.12 ±
0.75 ng/mg tissue).
Experimental design
The experimental rats were randomly divided into five
groups (n = 8–10 per group) 6 weeks after the 6-OHDA
lesion [17]. The 6-OHDA-lesioned groups were treated
with saline (0.9%, i.p.) or both L-DOPA (25 mg/kg, i.p.)
and benserazide (15 mg/kg, i.p.) at 10 am once a day
for 22 days. In addition, the 6-OHDA-lesioned groups
treated with L-DOPA (25 mg/kg, i.p.) were treated with
either GPS (25 and 50 mg/kg) or GP-EX (50 mg/kg) or-
ally (p.o.) 30 min prior to L-DOPA administration once
a day for 22 days [36] (Figure 1). After the last day of
GPS, GP-EX and L-DOPA treatment, rats were tested
for last AIMs score and contralateral rotation. Finally, the
rats were sacrificed for biochemical analysis including
ΔFosB expression and ERK1/2 phosphorylation.
Behavioral measurements
Rats were monitored for AIMs according to previously
published procedures and methods [17,37]. After treatmentwith L-DOPA, rats were observed individually for 1 min
every 20 min for 180 min period following dose of
L-DOPA. Observation was performed by trained ob-
servers who were blinded to the animal groupings and
experimental conditions. The AIMs were scored for
exhibition of the following four categories: (1) axial
AIMs, twisting movement of the neck, trunk and head
toward the side contralateral to the 6-OHDA lesion; (2)
limb AIMs, repetitive jerky movements or dystonic
posturing of the forelimb contralateral to the 6-OHDA
lesion; (3) orolingual AIMs, purposeless jaw movements
and contralateral tongue protrusion without the pres-
ence of food or other objects; (4) locomotive AIMs,
increased circular locomotion with contralateral side
bias. During the 1 min observation period, the four sub-
types were scored on a scale from 0 to 4 in each rat
based on the following criteria: 0, not present; 1, present
for less than half of the observation time; 2, present for
more than half of the observation time; 3, present all
the time but suppressible by threatening stimuli; 4,
present all the time and not suppressible. The axial,
limb, and orolingual AIMs were calculated by adding
each of the individual dyskinesia scores as body AIMs
(total AIMs). The body AIMs were also expressed by
the area under the curve of the each AIMs parameter.
Locomotive AIMs rating took into account the rat’s
circular movements on a flat floor using its all four
limbs, which were counted by only complete 360° turns.
The contralateral rotation was counted for 1 h and
started at 20 min after L-DOPA [36].
Western blotting
The rats were deeply anesthetized with Zoletil 50
(100 mg/kg, Virbac, Carros, France) and sacrificed by
rapid decapitation 1 h after L-DOPA treatment. The
brains were quickly removed and the striatum was iso-
lated on ice and homogenized in a lysis buffer. Protein
extracts from the striata of PD rats were prepared from
the left striata, and 20 μg protein from each rat was used
for western blotting [38]. The primary antibodies used
were rabbit polyclonal primary antibody (1:1000 dilu-
tion) against ΔFosB, phospho-ERK1/2, ERK1/2 and β-
actin. Proteins in samples (20μg) were separated using
10–15% sodium dodecyl sulfate-poly acrylamide gel elec-
trophoresis. Proteins were transferred to polyvinylidene
difluoride membrane at 300 mA for 1 h. The blots were
blocked for 1 h at room temperature in a fresh blocking
buffer (TBS-T containing 5% bovine serum albumin
[BSA]) and then incubated overnight at 4°C using primary
antibodies diluted 1:1000 in TBS-T with 5% BSA, and
for 1 h at room temperature using secondary antibodies
(anti-rabbit IgG HRP-linked antibodies, 1:5000 dilution
in TBS-T with 5% BSA), according to a standard pro-
cedure. The blots were then washed, and the transferred
Shin et al. BMC Neuroscience  (2015) 16:23 Page 9 of 10proteins were incubated with ECL substrate solution
(Amersham Pharmacia Biotech, Inc., Piscataway, NJ) for
5 min, according to the manufacturer’s instructions,
and visualized with a radiographic film.
Statistical analysis
Protein amounts were determined by a bicinchoninic acid
protein assay kit using BSA (Pierce Protein Research
Products, Rockford, IL). Behavioral data and group com-
parisons of dyskinesia intensity scores were analyzed by
non-parametric Kruskal-Wallis one-way ANOVA test for
multi-group comparisons at each day and Friedman re-
peated measures ANOVA test for two-group comparisons
unless otherwise indicated. Biochemical data were also
analyzed by one-way ANOVA followed by Tukey’s test.
All data were expressed as mean ± S.E.M. with P values of
< 0.05 being considered statistically significant.
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